Unboxing AI | Friday Webinars @ 11 AM ET | Dr Leonardo K Bittencourt, University Hospitals (July 12) | Kevin Harris, CureMetrix (July 19) | Dr Ryan Lee, Jefferson Health (July 26) | Register Now
  • 2019-08-14

Circulating Tumor DNA (ctDNA) – A Potential Adjunct to FDG-PET Imaging in Cancer Follow Up


  • With the continuous advances in healthcare - Next Generation Sequencing and PET-CT are revolutionising cancer diagnostics
  • Survival outcomes in cancer can be improved by early detection of metastatic disease or relapse during follow up
  • Next Generation sequencing is an extremely high end modality wherein hundreds to millions of DNA molecules are sequenced in parallel
  • CtDNA is an application of NGS to monitor the amount of tumor specific DNA in the peripheral blood of patient
  • Using ctDNA, a non-invasive investigation, to monitor the remission status can potentially reduce the frequency of imaging required at follow up, hence reducing the side effects and discomfort
  • According to Wong R et al, for colorectal cancer patients with indeterminate findings on routine investigations, ctDNA detection increases the probability that the findings indicate metastatic disease, including in a nonpredefined subset that also underwent FDG-PET imaging
  • Hence, using ctDNA as an adjunct to FDG-PET imaging during cancer follow-up seems to be an acceptable proposition.


  • What is ctDNA? How is it measured?
  • What are the current guidelines for cancer follow up?
  • Review of literature • Advantages and limitations of FDG-PET imaging
  • Advantages and limitations of ctDNA
  • Conclusion

Unlock the potential of CARPL platform for optimizing radiology workflows

Talk to a Clinical Solutions Architect